EGFR and neoplasm: In our study, TERTp mutations (77% vs. 56.4%, p = 0.01) and EGFR amplification (47.9 vs. 20.5%, p = 0.01) were more frequent in primary glioblastoma in comparison with recurrent tumor samples.